neurodegenerative disease
The firm's test measures three biomarkers to determine whether a patient has Alzheimer's disease or another form of dementia.
RetinalGenix Technologies Acquires DNA/GPS
The deal gives RetinalGenix rights to DNA/GPS's retinal imaging and genetic mapping technology for patient screening and early diagnosis.
Biomarker-Based Dx for Alzheimer's Rise as Study Results Question Effectiveness in Different Races
Premium
A paper published last month found that blood-based biomarkers used in diagnostic tests for Alzheimer's may not work as well in African American patients.
The firm obtained FDA breakthrough device designation in 2019 for its protein misfolding cyclic amplification technology and SynTap assay.
The approval of Biogen's Alzheimer's disease treatment in June was seen as an important regulatory development for companies developing tests.